Group 1: Product Pricing and Market Strategy - The price of the company's Huai Mi series products decreased by over 15% year-on-year, while the price of the Zhi Shi series products increased by over 35% year-on-year [4] - Future price trends will depend on raw material harvests and market competition; prices will decrease with abundant raw materials and increase with shortages [4] - The company aims to optimize product structure and reduce costs through new projects to mitigate price volatility risks [4] Group 2: Competitive Landscape - The plant extraction industry is highly segmented, with core products including natural pigments, plant essential oils, and active pharmaceutical ingredients [5] - Barriers to entry for competitors include overcoming technical extraction challenges and obtaining market access certifications [5] Group 3: Market Demand and Growth Potential - The global antioxidant market is projected to grow at a CAGR of 7.2% from 2023 to 2030, with plant extracts accounting for over 40% of the market [6] - The functional food market in China is expected to exceed 1.5 trillion yuan by 2025, driven by rising health demands and consumer spending [7] - The company's vitamin P products are anticipated to see sustained demand growth due to these market trends [7] Group 4: Core Technology and Production Capabilities - Key technological barriers in production include efficient extraction processes, stable large-scale production, and in-depth R&D capabilities [8] - The company has over ten years of experience in high-purity extraction, achieving over 99.5% purity for its quercetin products [8] - Continuous production techniques have improved extraction efficiency by over three times compared to traditional methods [8] Group 5: Strategic Development Plans - The company's development strategy involves three steps: deep processing of vitamin P raw materials, R&D of consumer-end products, and establishing a technical application center [9][11] - The strategy also includes dual market expansion in domestic and international markets, focusing on both pharmaceutical and food sectors [9][11] - The company plans to maintain growth by leveraging technological innovation and expanding into emerging markets like Southeast Asia [12]

Group 1: Investor Relations Activities - The company held a performance briefing for the 2024 annual report on April 29, 2025, via online communication [4] - Participants included the chairman, general manager, board secretary, financial officer, and sponsor representative [4] Group 2: Market Expansion and Product Certification - The company has obtained the EU export certification for its products, which requires compliance with the European Pharmacopoeia (CEP) and on-site inspections [5] - The company aims to enhance its competitiveness in the EU market by improving production quality and collaborating with EU clients [5] Group 3: Revenue Composition and Market Share - The company's revenue is primarily derived from pharmaceutical raw materials, food additives, cosmetics, and health products [6] - The European market accounts for approximately 40% of exports, while the US, Japan, Australia, and Canada account for about 60% [6] - The NHDC product has captured over 27% of the company's main business revenue in the domestic food additive market [6] Group 4: Growth Drivers and Strategic Focus - Future growth in the plant extract industry is driven by increasing consumer health awareness and advancements in extraction technology [8] - The company plans to deepen its focus on both domestic and international markets, particularly in food additives and pharmaceutical raw materials [9] Group 5: Financial Performance and Profit Margins - The company's revenue increased by 27.78% year-on-year in 2024, attributed to the successful implementation of its strategic plan [7] - The overall gross margin for products increased in 2024, but is expected to decline in 2025 due to rising costs and market competition [10] Group 6: Production and R&D Updates - The company is currently optimizing production processes and has completed 11 R&D projects in 2024 [15] - The new production lines are expected to be fully operational by mid-2025, which will enhance production capacity [14] Group 7: Market Trends and Future Outlook - The company anticipates a gradual recovery in gross margins as production lines stabilize and international trade conditions improve [12][13] - The market for Vitamin P products is expected to grow significantly due to rising health consciousness and expanding application areas [17]